30 results on '"Wang,Shusen"'
Search Results
2. Neoadjuvant pegylated liposomal doxorubicin-containing chemotherapy in combination with trastuzumab and pertuzumab in patients with HER2-positive early breast cancer: A randomized phase II study (METIS).
3. Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in previously treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Patient-reported outcomes (PROs) from the TROPION-Breast01 study.
4. Sacituzumab tirumotecan (SKB264/MK-2870) in patients (pts) with previously treated locally recurrent or metastatic triple-negative breast cancer (TNBC): Results from the phase III OptiTROP-Breast01 study.
5. Efficacy of abemaciclib versus tucidinostat after progression on palbociclib in patients with HR+/HER2− MBC: A multicenter retrospective cohort study.
6. Fragement C Gamma receptor IIIa polymorphism is predictive of trastuzumab efficacy in the neoadjuvant setting of HER2-positive breast cancer patients.
7. Tumor copy number alterations were associated with primary endocrine resistance in ER+ breast cancer.
8. A multiple center, open-label, single-arm, phase II clinical trial of MRG002, an HER2-targeted antibody-drug conjugate, in patients with HER2-low expressing advanced or metastatic breast cancer.
9. Safety of trastuzumab emtansine (T-DM1) in patients (pts) with HER2-positive locally advanced or metastatic breast cancer (mBC): Final results from KAMILLA Cohorts 1 (global) and 2 (Asia).
10. Efficacy of anlotinib in advanced soft tissue sarcoma by age, gender, and ECOG performance status.
11. [OPTIMAL 3] A phase III trial to evaluate the efficacy and safety of DHP107 (Liporaxel, oral paclitaxel) compared to Taxol (IV paclitaxel) as first line therapy in patients with recurrent or metastatic HER2 negative breast cancer (BC) (NCT03315364).
12. Evaluation of thyroid-stimulating hormone-increased, hypertriglyceridemia and proteinuria as markers of anlotinib efficacy in advanced soft tissue sarcoma.
13. Efficacy and safety of pegfilgrastim in prophylaxis of chemotherapy-induced neutropenia in breast cancer patients.
14. Pyrotinib or Lapatinib Combined With Capecitabine in HER2–Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study
15. Cost-effectiveness of primary prophylaxis with pegfilgrastim in early-stage breast cancer patients receiving chemotherapy in China.
16. Clinical genomic profiling to identify actionable alterations for very early relapsed triple-negative breast cancer patients in Chinese population.
17. Anlotinib for metastasis soft tissue sarcoma: A randomized, double-blind, placebo-controlled and multi-centered clinical trial.
18. Efficacy of mirtazapine in preventing delayed nausea and vomiting induced by highly emetogenic chemotherapy: An open-label, randomized, multicenter phase III trial.
19. Two-year follow-up of pretreatment anti-mullerian hormone (AMH) to predict for resumption of mense after chemotherapy in premenopausal hormone-receptor (HR+) positive early breast cancer (eBC).
20. Fulvestrant as maintenance therapy after first-line chemotherapy in patients with hormone receptor-positive, HER2-negative advanced breast cancer (FANCY), a prospective, multicenter, single arm phase 2 study.
21. Endocrine treatment-related symptoms and outcomes in breast cancer: A systematic review and meta-analysis.
22. Fulvestrant as maintenance therapy after first-line chemotherapy in postmenopausal hormone receptor-positive, HER2-negative advanced breast cancer patients (FANCY): A prospective, multicenter, single arm phase II study.
23. Prognosis and predictor role of PD-L1 expression in breast cancer patients between early recurrence and late recurrence.
24. Pretreatment anti-mullerian hormone to predict for resumption of mense in one year after chemotherapy in premenopausal hormone-receptor positive early breast cancer.
25. A multicenter, cross-sectional research of the adherence to endocrine therapy with selective estrogen receptor modulators (SERMs) in premenopausal women in China.
26. Phase II study of anlotinib for treatment of advanced soft tissues sarcomas.
27. IMM27M, a humanized Fc-engineered anti CTLA-4 antibody, in patients with advanced solid tumors: A phase I dose-escalation study.
28. Palbociclib, trastuzumab, pyrotinib and fulvestrant in patients with brain metastasis from ER/PR positive, HER-2 positive breast cancer: Report from an interim analysis of a multicenter, prospective study in China.
29. FS-1502 in HER2 -positive advanced breast cancer: Results from an open-label, phase 1 study.
30. LEONARDA-1: Phase III randomized study of lerociclib plus fulvestrant in patients with HR+, HER2- locally advanced or metastatic breast cancer that has progressed on prior endocrine therapy.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.